Who are MACRODANTIN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Furadantin, NITROFURANTOIN MACROCRYSTALS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nitrofurantoin-macrocrystalline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

MACRODANTIN — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MACRODANTIN (NITROFURANTOIN, MACROCRYSTALLINE) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitrofuran Antibacterial [EPC]. Area: Infectious Disease.

marketed Nitrofuran Antibacterial [EPC] Mitochondrial pyruvate carrier 2, CDGSH iron-sulfur domain-containing protein 1, Glucose-6-phosphate 1-dehydrogenase Infectious Disease Live · refreshed every 30 min

Target snapshot

MACRODANTIN (NITROFURANTOIN, MACROCRYSTALLINE) — ALMATICA.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MACRODANTIN TARGET	NITROFURANTOIN, MACROCRYSTALLINE	ALMATICA	marketed	Nitrofuran Antibacterial [EPC]	Mitochondrial pyruvate carrier 2, CDGSH iron-sulfur domain-containing protein 1, Glucose-6-phosphate 1-dehydrogenase
Furadantin	NITROFURANTOIN		marketed	Nitrofuran Antibacterial [EPC]	CDGSH iron-sulfur domain-containing protein 1	1953-01-01
NITROFURANTOIN MACROCRYSTALS	NITROFURANTOIN MACROCRYSTALS	HaEmek Medical Center, Israel	marketed	Nitrofuran Antibacterial [EPC]

Recent regulatory actions (last 90 days)

2026-04-07 — Furadantin · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitrofuran Antibacterial [EPC] class)

· 1 drug in this class
ALMATICA · 1 drug in this class
HaEmek Medical Center, Israel · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MACRODANTIN — Competitive Intelligence Brief. https://druglandscape.com/ci/nitrofurantoin-macrocrystalline. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing